Role of IgG antibodies in association with placental function and immunologic diseases in human pregnancy

Expert Review of Clinical Immunology

Volumn 9, Issue 3, 2013, Pages 235-249

  Malek, Antoine ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

ex vivo perfusion model; human pregnancy; IgG antibodies; immunologic diseases and therapy; placental function; placental transfer

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CYCLOSPORIN; FC RECEPTOR; HUMAN IMMUNOGLOBULIN; HUMAN PLACENTA LACTOGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; INFLIXIMAB; METHOTREXATE; PROPYLTHIOURACIL; RHESUS ANTIBODY; THIAMAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGIC DISEASE; ALLOIMMUNIZATION; ANTIGEN ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; CROHN DISEASE; ENTERITIS; EX VIVO STUDY; FEMALE; FETUS (ANATOMY); GOITER; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; HYPERTHYROIDISM; IN VIVO STUDY; INTRAUTERINE BLOOD TRANSFUSION; MESENCHYMAL STEM CELL; NEWBORN HEMOLYTIC DISEASE; PASSIVE IMMUNIZATION; PLACENTA DEVELOPMENT; PLACENTA FUNCTION; PLACENTAL TRANSFER; PREGNANCY; REVIEW; STEM CELL TRANSPLANTATION; SYNCYTIOTROPHOBLAST; THROMBOPHILIA; THYROID DISEASE; ULCERATIVE COLITIS;

ANTIBODIES; FEMALE; FETUS; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOGLOBULIN G; PLACENTA; PREGNANCY;

EID: 84874607489     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.99     Document Type: Review

References (134)

1. Parolini O, Alviano F, Bagnara GP et al. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells 26(2), 300-311 (2008).
2. Barlow S, Brooke G, Chatterjee K et al. Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev. 17(6), 1095-1107 (2008).
3. Prather WR, Toren A, Meiron M, Ofir R, Tschope C, Horwitz EM. The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemia. Cytotherapy 11(4), 427-434 (2009).
4. Portmann-Lanz CB, Schoeberlein A, Huber A et al. Placental mesenchymal stem cells as potential autologous graft for preand perinatal neuroregeneration. Am. J. Obstet. Gynecol. 194(3), 664-673 (2006).
5. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 22(7), 1338-1345 (2004).
6. Yen BL, Huang HI, Chien CC et al. Isolation of multipotent cells from human term placenta. Stem Cells 23(1), 3-9 (2005).
7. Semenov OV, Koestenbauer S, Riegel M et al. Multipotent mesenchymal stem cells from human placenta: critical parameters for isolation and maintenance of stemness after isolation. Am. J. Obstet. Gynecol. 202(2), 193.e1-193.e13 (2010).
8. Brooke G, Cook M, Blair C et al. Therapeutic applications of mesenchymal stromal cells. Semin. Cell Dev. Biol. 18(6), 846-858 (2007).
9. Enders AC, Blankenship TN. Comparative placental structure. Adv. Drug Deliv. Rev. 38(1), 3-15 (1999).
10. Carter AM. Animal models of human placentation-a review. Placenta 28, S41-S47 (2007).
11. Menezes V, Malek A, Keelan JA. Nanoparticulate drug delivery in pregnancy: placental passage and fetal exposure. Curr. Pharm. Biotechnol. 12(5), 731-742 (2011).
12. Malassiné A, Frendo JL, Evain-Brion D. A comparison of placental development and endocrine functions between the human and mouse model. Hum. Reprod. Update 9(6), 531-539 (2003).
13. McBride WG. Thalidomide embryopathy. Teratology 16(1), 79-82 (1977).
14. Stephens TD, Fillmore BJ. Hypothesis: thalidomide embryopathy-proposed mechanism of action. Teratology 61(3), 189-195 (2000).
15. Botting J. The History of Thalidomide. Drug News Perspect. 15(9), 604-611 (2002).
16. Enders AC. A Comparative study of the fine structure of the trophoblast in several hemochorial placentas. Am. J. Anat. 116, 29-67 (1965).
17. Enders AC, Carter AM. Review: the evolving placenta: different developmental paths to a hemochorial relationship. Placenta 33, S92-S98 (2012).
18. Moffett A, Loke C. Immunology of placentation in eutherian mammals. Nat. Rev. Immunol. 6(8), 584-594 (2006).
19. Carney EW, Scialli AR, Watson RE, DeSesso JM. Mechanisms regulating toxicant disposition to the embryo during early pregnancy: an interspecies comparison. Birth Defects Res. C. Embryo Today 72(4), 345-360 (2004).
20. Malek A, Sager R, Lang AB, Schneider H. Protein transport across the in vitro perfused human placenta. Am. J. Reprod. Immunol. 38(4), 263-271 (1997).
21. Brambell FW. The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet 2(7473), 1087-1093 (1966).
22. Kim J, Mohanty S, Ganesan LP et al. FcRn in the yolk sac endoderm of mouse is required for IgG transport to fetus. J. Immunol. 182(5), 2583-2589 (2009).
23. Leiser R, Dantzer V. Structural and functional aspects of porcine placental microvasculature. Anat. Embryol. 177(5), 409-419 (1988).
24. Cedard L, Yannotti S, Varangot J. The perfusion of the placenta in vitro used in the study of the biosynthesis of estrogens. C. R. Seances Soc. Biol. Fil. 155, 458-461 (1961).
25. Klinge E, Mattila MJ, Penttilä O, Jukarainen E. Influence of drugs on vasoactive peptides and amines in perfused human placenta. Ann. Med. Exp. Biol. Fenn. 44(3), 369-375 (1966).
26. Hensleigh PA, Krantz KE. Extracorporeal perfusion of the human placenta. I. Placental transfer of ascorbic acid. Am. J. Obstet. Gynecol. 96(1), 5-13 (1966).
27. Panigel M, Pascaud M, Brun JL. Radioangiographic study of circulation in the villi and intervillous space of isolated human placental cotyledon kept viable by perfusion. J. Physiol. (Paris) 59(Suppl. 1), 277 (1967).
28. Nesbitt RE Jr, Rice PA, Rourke JE, Torresi VF, Souchay AM. In vitro perfusion studies of the human placenta. A newly-designed apparatus for extracorporeal perfusion achieving dual closed circulation. Gynecol. Invest. 1(4), 185-203 (1970).
29. Malek A, Miller RK, Mattison DR et al. Continuous measurement of ATP by 31P-NMR in term human dually perfused placenta in vitro: response to ischemia. J. Appl. Physiol. 78(5), 1778-1786 (1995).
30. Malek A, Miller RK, Mattison DR et al. Energy charge monitoring via magnetic resonance spectroscopy 31P in the perfused human placenta: effects of cadmium, dinitrophenol and iodoacetate. Placenta 17(7), 495-506 (1996).
31. Myren M, Mose T, Mathiesen L, Knudsen LE. The human placenta - an alternative for studying foetal exposure. Toxicol. In Vitro 21(7), 1332-1340 (2007).
32. Malek A, Mattison DR. Drug development for use during pregnancy: impact of the placenta. Expert Rev. Obstet. Gynecol. 5(4), 437-454 (2010).
33. Sölder E, Rohr I, Kremser C, Hutzler P, Debbage PL. Imaging of placental transport mechanisms: a review. Eur. J. Obstet. Gynecol. Reprod. Biol. 144(Suppl. 1), S114-S120 (2009).
34. Ganapathy V, Prasad PD. Role of transporters in placental transfer of drugs. Toxicol. Appl. Pharmacol. 207(Suppl. 2), 381-387 (2005).
35. Ganapathy V, Prasad PD, Ganapathy ME, Leibach FH Placental transporters relevant to drug distribution across the maternal- fetal interface. J. Pharmacol. Exp. Ther. 294, 413-420 (2000).
36. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am. J. Reprod. Immunol. 36(5), 248-255 (1996).
37. Malek A, Sager R, Schneider H. Maternalfetal transport of immunoglobulin G and its subclasses during the third trimester of human pregnancy. Am. J. Reprod. Immunol. 32(1), 8-14 (1994).
38. Schneider H, Miller RK. Receptor-mediated uptake and transport of macromolecules in the human placenta. Int. J. Dev. Biol. 54(2-3), 367-375 (2010).
39. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am. J. Gastroenterol. 104(1), 228-233 (2009).
40. Brambell FWR. The passive immunity of the young mammal. Biol Rev. 3, 485-531 (1958).
41. Dancis J, Lind J, Oratz M, Smolens J, Vara P. Placental transfer of proteins in human gestation. Am. J. Obstet. Gynecol. 82, 167-171 (1961).
42. Linnet-Jepsen P, Galatius-Jensen F, Hauge M. On the inheritance of the Gm serum group. Acta Genet. Stat. Med. 8(2), 164-196 (1958).
43. Einhorn MS, Granoff DM, Nahm MH, Quinn A, Shackelford PG. Concentrations of antibodies in paired maternal and infant sera: relationship to IgG subclass. J. Pediatr. 111(5), 783-788 (1987).
44. Osuga T, Morishima T, Hanada N, Nishikawa K, Isobe K, Watanabe K. Transfer of specific IgG and IgG subclasses to herpes simplex virus across the blood- brain barrier and placenta in preterm and term newborns. Acta Paediatr. 81(10), 792-796 (1992).
45. Gros L, Pelegrin M, Plays M, Piechaczyk M. Efficient mother-to-child transfer of antiretroviral immunity in the context of preclinical monoclonal antibody-based immunotherapy. J. Virol. 80(20), 10191-10200 (2006).
46. Malek A, Sager R, Schneider H. Transport of proteins across the human placenta. Am. J. Reprod. Immunol. 40(5), 347-351 (1998).
47. Morell A, Skvaril F, van Loghem E, Kleemola M. Human IgG subclasses in maternal and fetal serum. Vox Sang. 21(6), 481-492 (1971).
48. Catty D, Drew R, Seger R. Transmission of IgG subclasses to the human fetus. In: Protein Transmission Through Living Membranes. Hemmings WA (Ed.). Elsevier, Amsterdam, UK, 37-43 (1979).
49. Yeung CY, Hobbs JR. Serum-gamma-Gglobulin levels in normal premature, post-mature, and "small-for-dates" newborn babies. Lancet 1(7553), 1167-1170 (1968).
50. Chandra RK. Levels of IgG subclasses, IgA, IgM, and tetanus antitoxin in paired maternal and fetal sera: findings in healthy pregnancies and placental insufficiency. In: Maternofetal Transmission of Immunoglobulins. Hemmings WA (Ed.). Cambridge University Press, Cambridge, UK, 77-87 (1976).
51. Gill TJ 3rd, Repetti CF, Metlay LA et al. Transplacental immunization of the human fetus to tetanus by immunization of the mother. J. Clin. Invest. 72(3), 987-996 (1983).
52. Vanderbeeken Y, Sarfati M, Bose R, Delespesse G. In utero immunization of the fetus to tetanus by maternal vaccination during pregnancy. Am. J. Reprod. Immunol. Microbiol. 8(2), 39-42 (1985).
53. Englund JA, Mbawuike IN, Hammill H, Holleman MC, Baxter BD, Glezen WP. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. J. Infect. Dis. 168(3), 647-656 (1993).
54. Takizawa T, Eguchi H, Namimatsu S, Jeschke U, Fuchs R, Robinson JM. Histochemistry for placenta research: theory and application. J. Nippon Med. Sch. 74(4), 268-273 (2007).
55. Malek A, Sager R, Zakher A, Schneider H. Transport of immunoglobulin G and its subclasses across the in vitro-perfused human placenta. Am. J. Obstet. Gynecol. 173(3 Pt 1), 760-767 (1995).
56. Saji F, Samejima Y, Kamiura S, Koyama M. Dynamics of immunoglobulins at the feto-maternal interface. Rev. Reprod. 4(2), 81-89 (1999).
57. Jones EA, Waldmann TA. The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J. Clin. Invest. 51(11), 2916-2927 (1972).
58. Rodewald R. Intestinal transport of antibodies in the newborn rat. J. Cell Biol. 58(1), 189-211 (1973).
59. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7(9), 715-725 (2007).
60. Wallace KH, Rees AR. Studies on the immunoglobulin-G Fc-fragment receptor from neonatal rat small intestine. Biochem. J. 188(1), 9-16 (1980).
61. Roberts DM, Guenthert M, Rodewald R. Isolation and characterization of the Fc receptor from the fetal yolk sac of the rat. J. Cell Biol. 111(5 Pt 1), 1867-1876 (1990).
62. Story CM, Mikulska JE, Simister NE. A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J. Exp. Med. 180(6), 2377-2381 (1994).
63. Simister NE, Story CM, Chen HL, Hunt JS. An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta. Eur. J. Immunol. 26(7), 1527-1531 (1996).
64. Kristoffersen EK, Matre R. Co-localization of β2-microglobulin and IgG in human placental syncytiotrophoblasts. Eur. J. Immunol. 26(2), 505-507 (1996).
65. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu. Rev. Immunol. 18, 739-766 (2000).
66. Firan M, Bawdon R, Radu C et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of γ-globulin in humans. Int. Immunol. 13(8), 993-1002 (2001).
67. Miller RK, Mace K, Polliotti B, DeRita R, Hall W, Treacy G. Marginal transfer of ReoPro (abciximab) compared with immunoglobulin G (F105), inulin and water in the perfused human placenta in vitro. Placenta 24(7), 727-738 (2003).
68. Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin. Dev. Immunol. 2008, 271363 (2008).
69. Brambell FWR. Transmission of passive immunity from mother to young and the catabolism of immunoglobulins. Lancet 2(7473), 1087-1093 (1966).
70. Wild EA. Transport of immunoglobulins and other proteins from mother to young. In: Lysosomes in Biology and Pathology (Volume 3). Dingle JT (Ed.). Elsevier, Amsterdam, The Netherlands, 169-215 (1973).
71. Wood GW, Bjerrum K, Johnson B. Detection of IgG bound within human trophoblast. J. Immunol. 129(4), 1479-1484 (1982).
72. Griffiths GD, Kershaw D, Booth AG. Rabbit peroxidase-antiperoxidase complex (PAP) as a model for the uptake of immunoglobulin G by the human placenta. Histochem. J. 17(8), 867-881 (1985).
73. Leach L, Eaton BM, Firth JA, Contractor SF. Uptake and intracellular routing of peroxidase-conjugated immunoglobulin-G by the perfused human placenta. Cell Tissue Res. 261(2), 383-388 (1990).
74. Kameda T, Koyama M, Matsuzaki N, Taniguchi T, Saji F, Tanizawa O. Localization of three subtypes of Fc gamma receptors in human placenta by immunohistochemical analysis. Placenta 12(1), 15-26 (1991).
75. Sedmak DD, Davis DH, Singh U, van de Winkel JG, Anderson CL. Expression of IgG Fc receptor antigens in placenta and on endothelial cells in humans. An immunohistochemical study. Am. J. Pathol. 138(1), 175-181 (1991).
76. Simister NE, Story CM. Human placental Fc receptors and the transmission of antibodies from mother to fetus. J. Reprod. Immunol. 37(1), 1-23 (1997).
77. Simister NE. Human placental Fc receptors and the trapping of immune complexes. Vaccine 16(14-15), 1451-1455 (1998).
78. Simister NE. Placental transport of immunoglobulin G. Vaccine 21(24), 3365-3369 (2003).
79. Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res. B. Dev. Reprod. Toxicol. 86(4), 328-344 (2009).
80. Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N. Engl. J. Med. 359(1), 61-73 (2008).
81. Prescott SL, Clifton V. Asthma and pregnancy: emerging evidence of epigenetic interactions in utero. Curr. Opin. Allergy Clin. Immunol. 9(5), 417-426 (2009).
82. Pincus-Knackstedt MK, Joachim RA, Blois SM et al. Prenatal stress enhances susceptibility of murine adult offspring toward airway inflammation. J. Immunol. 177(12), 8484-8492 (2006).
83. Wright RJ. Prenatal maternal stress and early caregiving experiences: implications for childhood asthma risk. Paediatr. Perinat. Epidemiol. 21(Suppl. 3), 8-14 (2007).
84. Cadavid AP, Bannenberg GL, Arck PC, Fitzgerald JS, Markert UR. Prevention and treatment of allergic asthma in pregnancy: from conventional drugs to new therapeutical approaches. Curr. Pharm. Biotechnol. 12(5), 758-764 (2011).
85. Kwon HL, Belanger K, Bracken MB. Asthma prevalence among pregnant and childbearing-aged women in the United States: estimates from national health surveys. Ann. Epidemiol. 13(5), 317-324 (2003).
86. Dombrowski MP, Schatz M; ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetriciangynecologists number 90, February 2008: asthma in pregnancy. Obstet. Gynecol. 111(2 Pt 1), 457-464 (2008).
87. Yawn B, Knudtson M. Treating asthma and comorbid allergic rhinitis in pregnancy. J. Am. Board Fam. Med. 20(3), 289-298 (2007).
88. Schatz M, Dombrowski MP. Clinical practice. Asthma in pregnancy. N. Engl. J. Med. 360(18), 1862-1869 (2009).
89. Simons FE, Schatz M. Anaphylaxis during pregnancy. J. Allergy Clin. Immunol. 130(3), 597-606 (2012).
90. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. J. Allergy Clin. Immunol. 115(3 Suppl. 2), S483-S523 (2005).
91. Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm. Bowel Dis. 16(5), 881-895 (2010).
92. Chaparro M, Gisbert JP. Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. Curr. Pharm. Biotechnol. 12(5), 765-773 (2011).
93. Lo YM, Corbetta N, Chamberlain PF et al. Presence of fetal DNA in maternal plasma and serum. Lancet 350(9076), 485-487 (1997).
94. Lo YM, Tein MS, Lau TK et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am. J. Hum. Genet. 62(4), 768-775 (1998).
95. Brinc D, Lazarus AH. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. Hematology Am. Soc. Hematol. Educ. Program 185-191 (2009).
96. Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Rev. 14(1), 44-61 (2000).
97. Finn R, Clarke CA, Donohoe WT et al. Experimental studies on the prevention of Rh haemolytic disease. Br. Med. J. 1(5238), 1486-1490 (1961).
98. Freda VJ, Gorman JG, Pollack W. Rh factor: prevention of isoimmunization and clinical trial on mothers. Science 151(3712), 828-830 (1966).
99. Uhr JW, Möller G. Regulatory effect of antibody on the immune response. Adv. Immunol. 8, 81-127 (1968).
100. Kumpel BM, Elson CJ. Mechanism of anti-D-mediated immune suppression - a paradox awaiting resolution? Trends Immunol. 22(1), 26-31 (2001)
101. Béliard R. Monoclonal anti-D antibodies to prevent alloimmunization: lessons from clinical trials. Transfus. Clin. Biol. 13(1-2), 58-64 (2006).
102. Kumpel BM. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang. 93(2), 99-111 (2007).
103. Heyman B. Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu. Rev. Immunol. 18, 709-737 (2000).
104. McHeyzer-Williams MG. B cells as effectors. Curr. Opin. Immunol. 15(3), 354-361 (2003).
105. Batista FD, Harwood NE. The who, how and where of antigen presentation to B cells. Nat. Rev. Immunol. 9(1), 15-27 (2009).
106. Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet. Gynecol. 112(1), 164-176 (2008).
107. Orange JS, Hossny EM, Weiler CR et al.; Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 117(Suppl. 4), S525-S553 (2006).
108. Sloan SR. Blood products used in the newborn. Manual of Neonatal Care (Sixth Edition). Cloherty JP, Eichenwald EC, Stark AR (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA, 463-469 (2008).
109. Alcock GS, Liley H. Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database Syst. Rev. 3, CD003313 (2002).
110. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst. Rev. 1, CD001239 (2004).
111. Fanaroff AA, Korones SB, Wright LL et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N. Engl. J. Med. 330(16), 1107-1113 (1994).
112. Miqdad AM, Abdelbasit OB, Shaheed MM, Seidahmed MZ, Abomelha AM, Arcala OP. Intravenous immunoglobulin G (IVIg) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. J. Matern. Fetal. Neonatal. Med. 16(3), 163-166 (2004).
113. van Kamp IL, Klumper FJ, Meerman RH, Oepkes D, Scherjon SA, Kanhai HH. Treatment of fetal anemia due to red-cell alloimmunization with intrauterine transfusions in The Netherlands, 1988-1999. Acta Obstet. Gynecol. Scand. 83(8), 731-737 (2004).
114. Van Kamp IL, Klumper FJ, Oepkes D et al. Complications of intrauterine intravascular transfusion for fetal anemia due to maternal red-cell alloimmunization. Am. J. Obstet. Gynecol. 192(1), 171-177 (2005).
115. Ghidini A, Sepulveda W, Lockwood CJ, Romero R. Complications of fetal blood sampling. Am. J. Obstet. Gynecol. 168(5), 1339-1344 (1993).
116. Radunovic N, Lockwood CJ, Alvarez M, Plecas D, Chitkara U, Berkowitz RL. The severly anemic and hydropic isoimmune fetus: changes in fetal hematocrit associated with intrauterine death. Obstet. Gynaecol. 79, 390-393 (1992).
117. Pierangeli SS, Leader B, Barilaro G, Willis R, Branch DW. Acquired and inherited thrombophilia disorders in pregnancy. Obstet. Gynecol. Clin. North Am. 38(2), 271-295 (2011).
118. Willis R, Harris EN, Pierangeli SS. Current international initiatives in antiphospholipid antibody testing. Semin. Thromb. Hemost. 38(4), 360-374 (2012).
119. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4(2), 295-306 (2006).
120. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 376(9751), 1498-1509 (2010).
121. Cervera R, Espinosa G. Antiphospholipid syndrome: long-time research on pathogenic mechanisms has finally lead to new therapeutic strategies. Expert Opin. Ther. Targets 14(12), 1279-1282 (2010).
122. Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr. Rev. 18(3), 404-433 (1997).
123. Kennedy RL, Malabu UH, Jarrod G, Nigam P, Kannan K, Rane A. Thyroid function and pregnancy: before, during and beyond. J. Obstet. Gynaecol. 30(8), 774-783 (2010).
124. Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. N. Engl. J. Med. 331(16), 1072-1078 (1994).
125. Gaberšcek S, Zaletel K. Thyroid physiology and autoimmunity in pregnancy and after delivery. Expert Rev. Clin. Immunol. 7(5), 697-706; quiz 707 (2011).
126. Brooke G, Rossetti T, Pelekanos R et al. Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials. Br. J. Haematol. 144, 571-579 (2009).
127. Malek A, Bersinger NA. Human placental stem cells: biomedical potential and clinical relevance. J. Stem Cells 6(2), 75-92 (2011).
128. Bieback K, Brinkmann I. Mesenchymal stromal cells from human perinatal tissues: From biology to cell therapy. World J. Stem Cells 2, 81-92 (2010).
129. Ankrum J, Karp JM. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol. Med. 16, 203-209 (2010).
130. Kontermann RE. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 23, 93-109 (2009).
131. Antiphospholipid Syndrome from NIH. www.ninds.nih.gov/disorders/ antiphosphlipid/antiphospholipid.htm
132. Antiphospholipid Antibody Syndrome and Pregnancy Treatment & Management. http://emedicine.medscape.com/article/261691-treatment
133. Thyroid Disease and Pregnancy. The American Thyroid Association. www.thyroid.org/patients/brochures/Thyroid-Dis-Pregnancy-broch.pdf
134. Grenon A: Stem cell treatment shows early promise: Celgene. Reuters, New York, 2010. www.reuters.com/article/idUSTRE63745M20100408